Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

NCT02903771 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions

DRUG: Part A: Dose Escalation of Cantrixil
DRUG: Part B: Expansion Cohort of Cantrixil

Sponsor

Kazia Therapeutics Limited